D-dopachrome tautomerase (D-DT or MIF-2): Doubling the MIF cytokine family

Cytokine

Volumn 59, Issue 1, 2012, Pages 10-17

  Merk, Melanie ^a   Mitchell, Robert A ^b   Endres, Stefan ^a   Bucala, Richard ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Cancer; CD74; MIF; Sepsis

Indexed keywords

BETA CATENIN; CD74 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CYCLOOXYGENASE 2; DOPACHROME TAUTOMERASE; ETANERCEPT; GLUCOCORTICOID; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; RAC1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; CANCER CELL; CYTOKINE RELEASE; DDT GENE; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG TARGETING; ENDOTOXEMIA; ENTERITIS; GENE; GENE STRUCTURE; GENETIC CONSERVATION; HUMAN; MACROPHAGE; MIF GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEPSIS; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; CONSERVED SEQUENCE; DISEASE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA;

ANIMALIA;

EID: 84861693249     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.03.014     Document Type: Review

References (117)

1. George M., Vaughan J.H. In vitro cell migration as a model for delayed hypersensitivity. Proc Soc Exp Biol Med 1962, 111:514-521.
2. Rich A.R., Lewis M.R. The nature of allergy in tuberculosis as revealed by tissue culture studies. Bull Johns Hopkins Hosp 1932, 50:115-131.
3. Calandra T., Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3:791-800.
4. Bloom B.R., Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966, 153:80-82.
5. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966, 56:72-77.
6. Bernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K.J., Voelter W., et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993, 365:756-759.
7. Calandra T., Bernhagen J., Mitchell R.A., Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179:1895-1902.
8. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377:68-71.
9. Leng L., Wang W., Roger T., Merk M., Wuttke M., Calandra T., et al. Glucocorticoid-induced MIF expression by human CEM T cells. Cytokine 2009, 48:177-185.
10. Flaster H., Bernhagen J., Calandra T., Bucala R. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol (Baltimore, MD) 2007, 21:1267-1280.
11. Merk M., Baugh J., Zierow S., Leng L., Pal U., Lee S.J., et al. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol 2009, 182:6896-6906.
12. Calandra T., Echtenacher B., Roy D.L., Pugin J., Metz C.N., Hultner L., et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000, 6:164-170.
13. Arjona A., Foellmer H.G., Town T., Leng L., McDonald C., Wang T., et al. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest 2007, 117:3059-3066.
14. Mizue Y., Ghani S., Leng L., McDonald C., Kong P., Baugh J., et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci USA 2005, 102:14410-14415.
15. Santos L.L., Dacumos A., Yamana J., Sharma L., Morand E.F. Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Clin Exp Immunol 2008, 152:372-380.
16. Leng L., Metz C.N., Fang Y., Xu J., Donnelly S., Baugh J., et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003, 197:1467-1476.
17. Shi X., Leng L., Wang T., Wang W., Du X., Li J., et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006, 25:595-606.
18. Binsky I., Haran M., Starlets D., Gore Y., Lantner F., Harpaz N., et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 2007, 104:13408-13413.
19. Weber C., Kraemer S., Drechsler M., Lue H., Koenen R.R., Kapurniotu A., et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA 2008, 105:16278-16283.
20. Bernhagen J., Krohn R., Lue H., Gregory J.L., Zernecke A., Koenen R.R., et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007, 13:587-596.
21. Gore Y., Starlets D., Maharshak N., Becker-Herman S., Kaneyuki U., Leng L., et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008, 283:2784-2792.
22. Meyer-Siegler K.L., Iczkowski K.A., Leng L., Bucala R., Vera P.L. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 2006, 177:8730-8739.
23. Heinrichs D., Knauel M., Offermanns C., Berres M.L., Nellen A., Leng L., et al. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci USA 2011, 108:17444-17449.
24. Odh G., Hindemith A., Rosengren A.M., Rosengren E., Rorsman H. Isolation of a new tautomerase monitored by the conversion of D-dopachrome to 5,6-dihydroxyindole. Biochem Biophys Res Commun 1993, 197:619-624.
25. Sugimoto H., Taniguchi M., Nakagawa A., Tanaka I., Suzuki M., Nishihira J. Crystal structure of human D-dopachrome tautomerase, a homologue of macrophage migration inhibitory factor, at 1.54A resolution. Biochemistry 1999, 38:3268-3279.
26. Sonesson B., Rosengren E., Hansson A.S., Hansson C. UVB-induced inflammation gives increased D-dopachrome tautomerase activity in blister fluid which correlates with macrophage migration inhibitory factor. Exp Dermatol 2003, 12:278-282.
27. Hiyoshi M., Konishi H., Uemura H., Matsuzaki H., Tsukamoto H., Sugimoto R., et al. D-Dopachrome tautomerase is a candidate for key proteins to protect the rat liver damaged by carbon tetrachloride. Toxicology 2009, 255:6-14.
28. Smyth R., Lane C.S., Ashiq R., Turton J.A., Clarke C.J., Dare T.O., et al. Proteomic investigation of urinary markers of carbon-tetrachloride-induced hepatic fibrosis in the Hanover Wistar rat. Cell Biol Toxicol 2009, 25:499-512.
29. Fu L., Liu Q., Shen L., Wang Y. Proteomic study on sodium selenite-induced apoptosis of human cervical cancer HeLa cells. J Trace Elem Med Biol 2011, 25:130-137.
30. Coleman A.M., Rendon B.E., Zhao M., Qian M.W., Bucala R., Xin D., et al. Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase. J Immunol 2008, 181:2330-2337.
31. Xin D., Rendon B.E., Zhao M., Winner M., McGhee Coleman A., Mitchell R.A. The MIF homologue D-dopachrome tautomerase promotes COX-2 expression through beta-catenin-dependent and -independent mechanisms. Mol Cancer Res 2010, 8:1601-1609.
32. Merk M., Zierow S., Leng L., Das R., Du X., Schulte W., et al. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci USA 2011, 108:E577-E585.
33. Bucala R. MIF and the genetic basis of macrophage responsiveness. Curr Immunol Rev 2006, 2:217-223.
34. Baugh J.A., Chitnis S., Donnelly S.C., Monteiro J., Lin X., Plant B.J., et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002, 3:170-176.
35. Radstake T.R., Sweep F.C., Welsing P., Franke B., Vermeulen S.H., Geurts-Moespot A., et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005, 52:3020-3029.
36. Sreih A., Ezzeddine R., Leng L., LaChance A., Yu G., Mizue Y., et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum 2011, 63:3942-3951.
37. Renner P., Roger T., Bochud P.Y., Sprong T., Sweep F.C., Bochud M., et al. A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J 2012, 26:907-916.
38. Meyer-Siegler K.L., Vera P.L., Iczkowski K.A., Bifulco C., Lee A., Gregersen P.K., et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun 2007, 8:646-652.
39. Wu S.P., Leng L., Feng Z., Liu N., Zhao H., McDonald C., et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006, 54:3661-3669.
40. Yende S., Angus D.C., Kong L., Kellum J.A., Weissfeld L., Ferrell R., et al. The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J 2009, 23:2403-2411.
41. Doernberg S., Schaaf B., Dalhoff K., Leng L., Beitin A., Quagliarello V., et al. Association of macrophage migration inhibitory factor (MIF) polymorphisms with risk of meningitis from Streptococcus pneumoniae. Cytokine 2011, 53:292-294.
42. Grigorenko E.L., Han S.S., Yrigollen C.M., Leng L., Mizue Y., Anderson G.M., et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 2008, 122:e438-e445.
43. Sun H.W., Bernhagen J., Bucala R., Lolis E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1996, 93:5191-5196.
44. Suzuki M., Sugimoto H., Nakagawa A., Tanaka I., Nishihira J., Sakai M. Crystal structure of the macrophage migration inhibitory factor from rat liver. Nat Struct Biol 1996, 3:259-266.
45. Lubetsky J.B., Dios A., Han J., Aljabari B., Ruzsicska B., Mitchell R., et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 2002, 277:24976-24982.
46. Fingerle-Rowson G., Kaleswarapu D.R., Schlander C., Kabgani N., Brocks T., Reinart N., et al. A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol Cell Biol 2009, 29:1922-1932.
47. Thiele M., Bernhagen J. Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid Redox Signal 2005, 7:1234-1248.
48. Kamir D., Zierow S., Leng L., Cho Y., Diaz Y., Griffith J., et al. A leishmania ortholog of macrophage migration inhibitory factor modulates host macrophage responses. J Immunol 2008, 180:8250-8261.
49. Sato A., Uinuk-ool T.S., Kuroda N., Mayer W.E., Takezaki N., Dongak R., et al. Macrophage migration inhibitory factor (MIF) of jawed and jawless fishes: implications for its evolutionary origin. Dev Comp Immunol 2003, 27:401-412.
50. Cho Y., Jones B.F., Vermeire J.J., Leng L., DiFedele L., Harrison L.M., et al. Structural and functional characterization of a secreted hookworm Macrophage Migration Inhibitory Factor (MIF) that interacts with the human MIF receptor CD74. J Biol Chem 2007, 282:23447-23456.
51. Falcone F.H., Loke P., Zang X., MacDonald A.S., Maizels R.M., Allen J.E. A Brugia malayi homolog of macrophage migration inhibitory factor reveals an important link between macrophages and eosinophil recruitment during nematode infection. J Immunol 2001, 167:5348-5354.
52. Augustijn K.D., Kleemann R., Thompson J., Kooistra T., Crawford C.E., Reece S.E., et al. Functional characterization of the Plasmodium falciparum and P. berghei homologues of macrophage migration inhibitory factor. Infect Immun 2007, 75:1116-1128.
53. Marson A.L., Tarr D.E., Scott A.L. Macrophage migration inhibitory factor (MIF) transcription is significantly elevated in Caenorhabditis elegans dauer larvae. Gene 2001, 278:53-62.
54. Vermeire J.J., Cho Y., Lolis E., Bucala R., Cappello M. Orthologs of macrophage migration inhibitory factor from parasitic nematodes. Trends Parasitol 2008, 24:355-363.
55. Bacher M., Meinhardt A., Lan H.Y., Mu W., Metz C.N., Chesney J.A., et al. Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 1997, 150:235-246.
56. Fingerle-Rowson G., Koch P., Bikoff R., Lin X., Metz C.N., Dhabhar F.S., et al. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol 2003, 162:47-56.
57. Esumi N., Budarf M., Ciccarelli L., Sellinger B., Kozak C.A., Wistow G. Conserved gene structure and genomic linkage for D-dopachrome tautomerase (DDT) and MIF. Mamm Genome 1998, 9:753-757.
58. Mitchell R.A., Liao H., Chesney J., Fingerle-Rowson G., Baugh J., David J., et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002, 99:345-350.
59. Hudson J.D., Shoaibi M.A., Maestro R., Carnero A., Hannon G.J., Beach D.H. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999, 190:1375-1382.
60. Mitchell R.A., Metz C.N., Peng T., Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999, 274:18100-18106.
61. Lue H., Kapurniotu A., Fingerle-Rowson G., Roger T., Leng L., Thiele M., et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 2006, 18:688-703.
62. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996, 93:7849-7854.
63. Calandra T., Bucala R. Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. J Inflamm 1995, 47:39-51.
64. Hermanowski-Vosatka A., Mundt S.S., Ayala J.M., Goyal S., Hanlon W.A., Czerwinski R.M., et al. Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry 1999, 38:12841-12849.
65. Bifulco C., McDaniel K., Leng L., Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des 2008, 14:3790-3801.
66. Rendon B.E., Willer S.S., Zundel W., Mitchell R.A. Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol 2009, 86:180-185.
67. Xu X., Wang B., Ye C., Yao C., Lin Y., Huang X., et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 2008, 261:147-157.
68. Hagemann T., Robinson S.C., Thompson R.G., Charles K., Kulbe H., Balkwill F.R. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther 2007, 6:1993-2002.
69. Wilson J.M., Coletta P.L., Cuthbert R.J., Scott N., MacLennan K., Hawcroft G., et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 2005, 129:1485-1503.
70. Hira E., Ono T., Dhar D.K., El-Assal O.N., Hishikawa Y., Yamanoi A., et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005, 103:588-598.
71. Fingerle-Rowson G., Petrenko O., Metz C.N., Forsthuber T.G., Mitchell R., Huss R., et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci USA 2003, 100:9354-9359.
72. Welford S.M., Bedogni B., Gradin K., Poellinger L., Broome Powell M., Giaccia A.J. HIF1alpha delays premature senescence through the activation of MIF. Genes Dev 2006, 20:3366-3371.
73. Martin J., Duncan F.J., Keiser T., Shin S., Kusewitt D.F., Oberyszyn T., et al. Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB) -induced nonmelanoma skin cancer (NMSC). FASEB J 2009, 23:720-730.
74. Ren Y., Law S., Huang X., Lee P.Y., Bacher M., Srivastava G., et al. Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg 2005, 242:55-63.
75. Ren Y., Chan H.M., Li Z., Lin C., Nicholls J., Chen C.F., et al. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene 2004, 23:4146-4154.
76. White E.S., Flaherty K.R., Carskadon S., Brant A., Iannettoni M.D., Yee J., et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 2003, 9:853-860.
77. Rendon B.E., Roger T., Teneng I., Zhao M., Al-Abed Y., Calandra T., et al. Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 2007, 282:29910-29918.
78. Lue H., Dewor M., Leng L., Bucala R., Bernhagen J. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal 2011, 23:135-144.
79. Hawkins P.T., Eguinoa A., Qiu R.G., Stokoe D., Cooke F.T., Walters R., et al. PDGF stimulates an increase in GTP-Rac via activation of phosphoinositide 3-kinase. Curr Biol 1995, 5:393-403.
80. Clark E.A., King W.G., Brugge J.S., Symons M., Hynes R.O. Integrin-mediated signals regulated by members of the rho family of GTPases. J Cell Biol 1998, 142:573-586.
81. Tohyama S., Onodera S., Tohyama H., Yasuda K., Nishihira J., Mizue Y., et al. A novel DNA vaccine-targeting macrophage migration inhibitory factor improves the survival of mice with sepsis. Gene Ther 2008, 15:1513-1522.
82. Chuang C.C., Wang S.T., Chen W.C., Chen C.C., Hor L.I., Chuang A.Y. Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality. Shock 2007, 27:503-506.
83. Sprong T., Pickkers P., Geurts-Moespot A., van der Ven-Jongekrijg J., Neeleman C., Knaup M., et al. Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock 2007, 27:482-487.
84. Bozza F.A., Gomes R.N., Japiassu A.M., Soares M., Castro-Faria-Neto H.C., Bozza P.T., et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004, 22:309-313.
85. Bozza M., Satoskar A.R., Lin G., Lu B., Humbles A.A., Gerard C., et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999, 189:341-346.
86. Al-Abed Y., Dabideen D., Aljabari B., Valster A., Messmer D., Ochani M., et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 2005, 280:36541-36544.
87. Bouchon A., Facchetti F., Weigand M.A., Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001, 410:1103-1107.
88. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
89. Emonts M., Sweep F.C., Grebenchtchikov N., Geurts-Moespot A., Knaup M., Chanson A.L., et al. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 2007, 44:1321-1328.
90. Kerschbaumer R.J., Rieger M., Volkel D., Le Roy D., Roger T., Garbaraviciene J., et al. Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the beta-sheet structure of MIF. J Biol Chem 2012, 287:7446-7455.
91. Leng L., Chen L., Fan J., Greven D., Arjona A., Du X., et al. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol 2011, 186:527-538.
92. Berkova Z., Tao R.H., Samaniego F. Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs 2010, 19:141-149.
93. Chen P.F., Luo Y.L., Wang W., Wang J.X., Lai W.Y., Hu S.M., et al. ISO-1, a macrophage migration inhibitory factor antagonist, inhibits airway remodeling in a murine model of chronic asthma. Mol Med 2010, 16:400-408.
94. Amano T., Nishihira J., Miki I. Blockade of macrophage migration inhibitory factor (MIF) prevents the antigen-induced response in a murine model of allergic airway inflammation. Inflamm Res 2007, 56:24-31.
95. Kobayashi M., Nasuhara Y., Kamachi A., Tanino Y., Betsuyaku T., Yamaguchi E., et al. Role of macrophage migration inhibitory factor in ovalbumin-induced airway inflammation in rats. Eur Respir J 2006, 27:726-734.
96. Yamaguchi E., Nishihira J., Shimizu T., Takahashi T., Kitashiro N., Hizawa N., et al. Macrophage migration inhibitory factor (MIF) in bronchial asthma. Clin Exp Allergy 2000, 30:1244-1249.
97. Burger-Kentischer A., Gobel H., Kleemann R., Zernecke A., Bucala R., Leng L., et al. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis 2006, 184:28-38.
98. Chen Z., Sakuma M., Zago A.C., Zhang X., Shi C., Leng L., et al. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol 2004, 24:709-714.
99. Pan J.H., Sukhova G.K., Yang J.T., Wang B., Xie T., Fu H., et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2004, 109:3149-3153.
100. Burger-Kentischer A., Goebel H., Seiler R., Fraedrich G., Schaefer H.E., Dimmeler S., et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002, 105:1561-1566.
101. He X.X., Chen K., Yang J., Li X.Y., Gan H.Y., Liu C.Y., et al. Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 2009, 15:1-10.
102. Lee H., Rhee H., Kang H.J., Kim H.S., Min B.S., Kim N.K., et al. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol 2008, 129:772-779.
103. Hoi A.Y., Hickey M.J., Hall P., Yamana J., O'Sullivan K.M., Santos L.L., et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 2006, 177:5687-5696.
104. Foote A., Briganti E.M., Kipen Y., Santos L., Leech M., Morand E.F. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004, 31:268-273.
105. Nicoletti F., Creange A., Orlikowski D., Bolgert F., Mangano K., Metz C., et al. Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. J Neuroimmunol 2005, 168:168-174.
106. Dagia N.M., Kamath D.V., Bhatt P., Gupte R.D., Dadarkar S.S., Fonseca L., et al. A fluorinated analog of ISO-1 blocks the recognition and biological function of MIF and is orally efficacious in a murine model of colitis. Eur J Pharmacol 2009, 607:201-212.
107. de Jong Y.P., Abadia-Molina A.C., Satoskar A.R., Clarke K., Rietdijk S.T., Faubion W.A., et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001, 2:1061-1066.
108. Ohkawara T., Koyama Y., Onodera S., Takeda H., Kato M., Asaka M., et al. DNA vaccination targeting macrophage migration inhibitory factor prevents murine experimental colitis. Clin Exp Immunol 2011, 163:113-122.
109. Ohkawara T., Nishihira J., Takeda H., Hige S., Kato M., Sugiyama T., et al. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 2002, 123:256-270.
110. Oliver J., Marquez A., Gomez-Garcia M., Martinez A., Mendoza J.L., Vilchez J.R., et al. Association of the macrophage migration inhibitory factor gene polymorphisms with inflammatory bowel disease. Gut 2007, 56:150-151.
111. Kithcart A.P., Cox G.M., Sielecki T., Short A., Pruitt J., Papenfuss T., et al. A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J 2010, 24:4459-4466.
112. Denkinger C.M., Denkinger M., Kort J.J., Metz C., Forsthuber T.G. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 2003, 170:1274-1282.
113. Akcali A., Pehlivan S., Pehlivan M., Sever T., Neyal M. Association of macrophage migration inhibitory factor gene promoter polymorphisms with multiple sclerosis in Turkish patients. J Int Med Res 2010, 38:69-77.
114. Niino M., Ogata A., Kikuchi S., Tashiro K., Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J Neurol Sci 2000, 179:127-131.
115. Mikulowska A., Metz C.N., Bucala R., Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol 1997, 158:5514-5517.
116. Leech M., Metz C., Santos L., Peng T., Holdsworth S.R., Bucala R., et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 1998, 41:910-917.
117. Lehmann L.E., Book M., Hartmann W., Weber S.U., Schewe J.C., Klaschik S., et al. A MIF haplotype is associated with the outcome of patients with severe sepsis: a case-control study. J Transl Med 2009, 7:100.